# Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

> **NCT03451422** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 35 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Efavaleukin Alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03451422
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-10
- **Primary completion:** 2021-10-12
- **Final completion:** 2021-10-12
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03451422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03451422, "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03451422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*